

Mark B Faries

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8020193/publications.pdf>

Version: 2024-02-01

126
papers

9,007
citations

70961

41
h-index

42291

92
g-index

128
all docs

128
docs citations

128
times ranked

7881
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Re: "Time to reconsider the role of sentinel lymph node biopsy in melanoma", Journal of the American Academy of Dermatology, 2023, 88, e25-e26. | 0.6 | 3 |
| 2 | The lymphatic system and sentinel lymph nodes: conduit for cancer metastasis. Clinical and Experimental Metastasis, 2022, 39, 139-157. | 1.7 | 23 |
| 3 | Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). Annals of Surgical Oncology, 2022, 29, 3694-3708. | 0.7 | 21 |
| 4 | Sentinel lymph node melanoma metastases: Assessment of tumor burden for clinical prediction of outcome in the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). European Journal of Surgical Oncology, 2022, 48, 1280-1287. | 0.5 | 7 |
| 5 | Quantitative Nodal Burden and Mortality Across Solid Cancers. Journal of the National Cancer Institute, 2022, 114, 1003-1011. | 3.0 | 4 |
| 6 | Melanoma trials that defined surgical management. Journal of Surgical Oncology, 2022, 125, 34-37. | 0.8 | 2 |
| 7 | ASO Author Reflections: Minimally Invasive Inguinal Lymphadenectomy, an Incremental Step in the Evolution of the Management of Advanced Melanoma. Annals of Surgical Oncology, 2022, , . | 0.7 | 0 |
| 8 | ASO Visual Abstract: Oncologic Outcomes of Multi-Institutional Minimally Invasive Inguinal Lymph Node Dissection for Melanoma Compared with Open Inguinal Dissection in MSLT-II. Annals of Surgical Oncology, 2022, , 1. | 0.7 | 0 |
| 9 | Oncologic Outcomes of Multi-Institutional Minimally Invasive Inguinal Lymph Node Dissection for Melanoma Compared with Open Inguinal Dissection in the Second Multicenter Selective Lymphadenectomy Trial (MSLT-II). Annals of Surgical Oncology, 2022, , 1. | 0.7 | 4 |
| 10 | Patterns of Recurrence and Prognosis in Pathologic Stage I and II Merkel Cell Carcinoma: A multi-center, retrospective cohort analysis. Journal of the American Academy of Dermatology, 2022, , . | 0.6 | 0 |
| 11 | Quantitative metastatic lymph node burden and survival in Merkel cell carcinoma. Journal of the American Academy of Dermatology, 2021, 84, 312-320. | 0.6 | 17 |
| 12 | Preoperative Ultrasound Assessment of Regional Lymph Nodes in Melanoma Patients Does not Provide Reliable Nodal Staging. Annals of Surgery, 2021, 273, 814-820. | 2.1 | 16 |
| 13 | A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary Analysis. Annals of Surgical Oncology, 2021, 28, 6126-6137. | 0.7 | 16 |
| 14 | Predictors of False Negative Sentinel Lymph Node Biopsy in Clinically Localized Merkel Cell Carcinoma. Annals of Surgical Oncology, 2021, 28, 6995-7003. | 0.7 | 8 |
| 15 | Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis. Cancer Medicine, 2021, 10, 4302-4311. | 1.3 | 6 |
| 16 | Recent Advances in the Treatment of Melanoma. New England Journal of Medicine, 2021, 384, 2229-2240. | 13.9 | 201 |
| 17 | Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma. Melanoma Research, 2021, 31, 378-388. | 0.6 | 3 |
| 18 | Donald L. Morton Memorial Lecture: the legacy of Donald Morton: past, present and future. Clinical and Experimental Metastasis, 2021, , 1. | 1.7 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Development and Validation of a Modified Pathologic Nodal Classification System for Cutaneous Melanoma. JAMA Surgery, 2021, 156, e214298. | 2.2 | 1 |
| 20 | Letter Regarding Editorial by Samuel Zagarella. American Journal of Dermatopathology, 2021, 43, 539-541. | 0.3 | 2 |
| 21 | 381â€¦Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study. , 2021, 9, A415-A415. | | 2 |
| 22 | The Landmark Series: MSLT-1, MSLT-2 and DeCOG (Management of Lymph Nodes). Annals of Surgical Oncology, 2020, 27, 15-21. | 0.7 | 56 |
| 23 | Parathyroidectomy for Patients With Primary Hyperparathyroidism and Associations With Hypertension. JAMA Surgery, 2020, 155, 32. | 2.2 | 19 |
| 24 | ASO Author Reflections: The Past, Present, and Future of Managing Melanoma Lymph Node Metastases: What the Trials Tell Us. Annals of Surgical Oncology, 2020, 27, 735-736. | 0.7 | 0 |
| 25 | Regional Node Basin Recurrence in Melanoma Patients: More Common After Node Dissection for Macroscopic Rather than Clinically Occult Nodal Disease. Annals of Surgical Oncology, 2020, 27, 1970-1977. | 0.7 | 3 |
| 26 | Comment on â€œFactors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive Nomogramâ€• Journal of Clinical Oncology, 2020, 38, 3233-3234. | 0.8 | 4 |
| 27 | Improved Tool for Predicting Sentinel Lymph Node Metastases in Melanoma. Journal of Clinical Oncology, 2020, 38, 2706-2708. | 0.8 | 4 |
| 28 | Sentinel Lymph Node Biopsy for Melanoma: Buggy Whip or Roller Bearing?. Annals of Surgical Oncology, 2020, 27, 2586-2588. | 0.7 | 1 |
| 29 | Systemic Therapy for Melanoma: ASCO Guideline. Journal of Clinical Oncology, 2020, 38, 3947-3970. | 0.8 | 190 |
| 30 | Surgical Management of Distant Melanoma Metastases. , 2020, , 1359-1402. | | 1 |
| 31 | Sentinel Lymph Node Biopsy. Surgical Oncology Clinics of North America, 2020, 29, 401-414. | 0.6 | 3 |
| 32 | Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncology, The, 2019, 20, e378-e389. | 5.1 | 155 |
| 33 | Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma. Cancers, 2019, 11, 1642. | 1.7 | 47 |
| 34 | ASO Author Reflections: What Role Do Surgeons Play in the Era of Effective Systemic Therapy for Melanoma?. Annals of Surgical Oncology, 2019, 26, 4619-4620. | 0.7 | 2 |
| 35 | Impact of Effective Systemic Therapy on Metastasectomy in Stage IV Melanoma: A Matched-Pair Analysis. Annals of Surgical Oncology, 2019, 26, 4610-4618. | 0.7 | 20 |
| 36 | Recurrence of Melanoma After a Negative Sentinel Node Biopsy: Predictors and Impact of Recurrence Site on Survival. Annals of Surgical Oncology, 2019, 26, 2254-2262. | 0.7 | 26 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 37 | Response to Comment on "Preoperative Ultrasound Assessment of Regional Lymph Nodes in Melanoma Patients Does Not Provide Reliable Staging." <i>Annals of Surgery</i> , 2019, Publish Ahead of Print, e104-e105. | 2.1 | 9 |
| 38 | Microsatellitosis in Patients with Melanoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 33-41. | 0.7 | 11 |
| 39 | Age-Related Changes in HAPLN1 Increase Lymphatic Permeability and Affect Routes of Melanoma Metastasis. <i>Cancer Discovery</i> , 2019, 9, 82-95. | 7.7 | 100 |
| 40 | Surgical Management of Distant Melanoma Metastases. , 2019, , 1-44. | | 0 |
| 41 | More on Adjuvant Therapy in Resected Melanoma. <i>New England Journal of Medicine</i> , 2018, 378, 1656-1657. | 13.9 | 5 |
| 42 | Predicting the incidence and timing of central nervous system disease in metastatic melanoma: Implications for surveillance and preventative therapy. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 419-421. | 0.6 | 2 |
| 43 | Completing the Dissection in Melanoma: Increasing Decision Precision. <i>Annals of Surgical Oncology</i> , 2018, 25, 585-587. | 0.7 | 7 |
| 44 | Authentication of M14 melanoma cell line proves misidentification of MDA-MB-435 breast cancer cell line. <i>International Journal of Cancer</i> , 2018, 142, 561-572. | 2.3 | 37 |
| 45 | Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. <i>Annals of Surgical Oncology</i> , 2018, 25, 356-377. | 0.7 | 130 |
| 46 | Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2018, 36, 399-413. | 0.8 | 190 |
| 47 | Omitting Completion Dissection in Melanoma? Help is Available for Surgeons Coping Without Routine Dissection, But More Work is Needed. <i>Annals of Surgical Oncology</i> , 2018, 25, 3416-3418. | 0.7 | 3 |
| 48 | Lymph node metastasis in melanoma: a debate on the significance of nodal metastases, conditional survival analysis and clinical trials. <i>Clinical and Experimental Metastasis</i> , 2018, 35, 431-442. | 1.7 | 16 |
| 49 | Safety and Feasibility of Minimally Invasive Inguinal Lymph Node Dissection in Patients With Melanoma (SAFE-MILND). <i>Annals of Surgery</i> , 2017, 265, 192-196. | 2.1 | 39 |
| 50 | The Impact of Smoking on Sentinel Node Metastasis of Primary Cutaneous Melanoma. <i>Annals of Surgical Oncology</i> , 2017, 24, 2089-2094. | 0.7 | 22 |
| 51 | Is Pregnancy-Associated Melanoma Associated with Adverse Outcomes?. <i>Journal of the American College of Surgeons</i> , 2017, 225, 149-158. | 0.2 | 13 |
| 52 | Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. <i>New England Journal of Medicine</i> , 2017, 376, 2211-2222. | 13.9 | 1,087 |
| 53 | The prognostic importance of scalp location in primary head and neck melanoma. <i>Journal of Surgical Oncology</i> , 2017, 116, 337-343. | 0.8 | 28 |
| 54 | Association of Surgical Treatment, Systemic Therapy, and Survival in Patients With Abdominal Visceral Melanoma Metastases, 1965-2014. <i>JAMA Surgery</i> , 2017, 152, 672. | 2.2 | 57 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-------|-----------|
| 55 | Laparoscopic skill assessment of practicing surgeons prior to enrollment in a surgical trial of a new laparoscopic procedure. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2017, 31, 3313-3319. | 1.3 | 17 |
| 56 | Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases. <i>Annals of Surgical Oncology</i> , 2017, 24, 3991-4000. | 0.7 | 102 |
| 57 | Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 472-492. | 157.7 | 1,662 |
| 58 | Regarding complications following completion lymphadenectomy. <i>European Journal of Surgical Oncology</i> , 2017, 43, 2374-2375. | 0.5 | 0 |
| 59 | Impact of Time Between Diagnosis and SLNB on Outcomes in Cutaneous Melanoma. <i>Journal of the American College of Surgeons</i> , 2017, 225, 302-311. | 0.2 | 20 |
| 60 | Thin Melanoma with Nodal Involvement: Analysis of Demographic, Pathologic, and Treatment Factors with Regard to Prognosis. <i>Annals of Surgical Oncology</i> , 2017, 24, 952-959. | 0.7 | 23 |
| 61 | <i>Mycobacterium bovis</i> Bacillus Calmette-Guérin Alters Melanoma Microenvironment Favoring Antitumor T Cell Responses and Improving M2 Macrophage Function. <i>Frontiers in Immunology</i> , 2017, 8, 965. | 2.2 | 32 |
| 62 | Insights into Local Tumor Microenvironment Immune Factors Associated with Regression of Cutaneous Melanoma Metastases by <i>Mycobacterium bovis</i> Bacille Calmette-Guérin. <i>Frontiers in Oncology</i> , 2017, 7, 61. | 1.3 | 24 |
| 63 | Prognostic Value of Multiple Draining Lymph Node Basins in Melanoma: A Matched-Pair Analysis Based on the John Wayne Cancer Institute Experience. <i>Frontiers in Oncology</i> , 2017, 7, 172. | 1.3 | 6 |
| 64 | Training High-Volume Melanoma Surgeons to Perform a Novel Minimally Invasive Inguinal Lymphadenectomy: Report of a Prospective Multi-Institutional Trial. <i>Journal of the American College of Surgeons</i> , 2016, 222, 253-260. | 0.2 | 16 |
| 65 | Impact of Completion Lymph Node Dissection on Patients with Positive Sentinel Lymph Node Biopsy in Melanoma. <i>Journal of the American College of Surgeons</i> , 2016, 223, 9-18. | 0.2 | 30 |
| 66 | Predictors and Survival Impact of False-Negative Sentinel Nodes in Melanoma. <i>Annals of Surgical Oncology</i> , 2016, 23, 1012-1018. | 0.7 | 49 |
| 67 | Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver Metastases. <i>Annals of Surgical Oncology</i> , 2016, 23, 1309-1319. | 0.7 | 117 |
| 68 | Evolving Therapeutic Strategies in Mucosal Melanoma Have Not Improved Survival Over Five Decades. <i>American Surgeon</i> , 2016, 82, 1-5. | 0.4 | 18 |
| 69 | Second Primary Melanoma: Risk Factors, Histopathologic Features, Survival, and Implications for Follow-Up. <i>American Surgeon</i> , 2016, 82, 1009-1013. | 0.4 | 13 |
| 70 | Adrenalectomy for Metastatic Melanoma: Current Role in the Age of Nonsurgical Treatments. <i>American Surgeon</i> , 2015, 81, 1005-1009. | 0.4 | 26 |
| 71 | From the Guest Editor. <i>Cancer Journal (Sudbury, Mass)</i> , 2015, 21, 1-2. | 1.0 | 1 |
| 72 | Attitudes and Perceptions of Surgical Oncology Fellows on ACGME Accreditation and the Complex General Surgical Oncology Certification. <i>Annals of Surgical Oncology</i> , 2015, 22, 3776-3784. | 0.7 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 73 | Adrenalectomy for Metastatic Melanoma: Current Role in the Age of Nonsurgical Treatments. <i>American Surgeon</i> , 2015, 81, 1005-9. | 0.4 | 11 |
| 74 | Sentinel Lymph Node Biopsy for Melanoma: A Plea to Let the Data be Heard. <i>Annals of Surgical Oncology</i> , 2014, 21, 3362-3364. | 0.7 | 4 |
| 75 | Clinical Benefit from Ipilimumab Therapy in Melanoma Patients may be Associated with Serum CTLA4 Levels. <i>Frontiers in Oncology</i> , 2014, 4, 110. | 1.3 | 51 |
| 76 | Final Trial Report of Sentinel-Node Biopsy versus Nodal Observation in Melanoma. <i>New England Journal of Medicine</i> , 2014, 370, 599-609. | 13.9 | 1,203 |
| 77 | Sentinel-Node Biopsy in Melanoma. <i>New England Journal of Medicine</i> , 2014, 370, 2148-2150. | 13.9 | 11 |
| 78 | Melanoma Vaccines. <i>Surgical Clinics of North America</i> , 2014, 94, 1017-1030. | 0.5 | 36 |
| 79 | A 20-Year Experience of Hepatic Resection for Melanoma: Is There an Expanding Role?. <i>Journal of the American College of Surgeons</i> , 2014, 219, 62-68. | 0.2 | 41 |
| 80 | Combined Analysis of Phase III Trials Evaluating [99mTc]Tilmanocept and Vital Blue Dye for Identification of Sentinel Lymph Nodes in Clinically Node-Negative Cutaneous Melanoma. <i>Annals of Surgical Oncology</i> , 2013, 20, 680-688. | 0.7 | 138 |
| 81 | Anorectal Malignant Melanoma: Extensive 45-Year Review and Proposal for a Novel Staging Classification. <i>Journal of the American College of Surgeons</i> , 2013, 217, 324-335. | 0.2 | 59 |
| 82 | Late Recurrence in Melanoma: Clinical Implications of Lost Dormancy. <i>Journal of the American College of Surgeons</i> , 2013, 217, 27-34. | 0.2 | 86 |
| 83 | Comparative Evaluation of [99mTc]Tilmanocept for Sentinel Lymph Node Mapping in Breast Cancer Patients: Results of Two Phase 3 Trials. <i>Annals of Surgical Oncology</i> , 2013, 20, 2590-2599. | 0.7 | 101 |
| 84 | Staging of Regional Lymph Nodes in Melanoma. <i>JAMA Surgery</i> , 2013, 148, 879. | 2.2 | 48 |
| 85 | Assessment of Prognostic Circulating Tumor Cells in a Phase III Trial of Adjuvant Immunotherapy After Complete Resection of Stage IV Melanoma. <i>Annals of Surgery</i> , 2012, 255, 357-362. | 2.1 | 83 |
| 86 | Combined Intralesional Bacille Calmette-Guérin (BCG) and Topical Imiquimod for In-transit Melanoma. <i>Journal of Immunotherapy</i> , 2012, 35, 716-720. | 1.2 | 75 |
| 87 | Association Between Circulating Tumor Cells and Prognosis in Patients With Stage III Melanoma With Sentinel Lymph Node Metastasis in a Phase III International Multicenter Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 3819-3826. | 0.8 | 77 |
| 88 | Metastasectomy for Distant Metastatic Melanoma: Analysis of Data from the First Multicenter Selective Lymphadenectomy Trial (MSLT-I). <i>Annals of Surgical Oncology</i> , 2012, 19, 2547-2555. | 0.7 | 155 |
| 89 | Staging of Regional Nodes in Pulmonary Malignancies. <i>Annals of Surgical Oncology</i> , 2012, 19, 703-705. | 0.7 | 2 |
| 90 | Epitrochlear sentinel lymph nodes in melanoma: interval or independent?. <i>American Surgeon</i> , 2012, 78, 702-5. | 0.4 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Current Surgical Treatment in Melanoma. <i>Current Problems in Cancer</i> , 2011, 35, 173-184. | 1.0 | 5 |
| 92 | Melanoma Brain Metastases: Is It Time to Reassess the Bias?. <i>Current Problems in Cancer</i> , 2011, 35, 200-210. | 1.0 | 33 |
| 93 | Management of Popliteal Sentinel Nodes in Melanoma. <i>Journal of the American College of Surgeons</i> , 2011, 213, 180-186. | 0.2 | 20 |
| 94 | A Phase 2 Study of 99mTc-Tilmanocept in the Detection of Sentinel Lymph Nodes in Melanoma and Breast Cancer. <i>Annals of Surgical Oncology</i> , 2011, 18, 961-969. | 0.7 | 68 |
| 95 | Factors Predictive of the Status of Sentinel Lymph Nodes in Melanoma Patients from a Large Multicenter Database. <i>Annals of Surgical Oncology</i> , 2011, 18, 3593-3600. | 0.7 | 78 |
| 96 | Reply to Letter to the Editor "Lymphoedema in the Observation and Biopsy Arms of MSLT-1" by Thomas, J Meirion (ASO-2011-04-0666). <i>Annals of Surgical Oncology</i> , 2011, 18, 312-314. | 0.7 | 0 |
| 97 | Predictors of Occult Nodal Metastasis in Patients With Thin Melanoma. <i>Archives of Surgery</i> , 2010, 145, 137. | 2.3 | 48 |
| 98 | Practice Patterns and Outcomes for Anorectal Melanoma in the USA, Reviewing Three Decades of Treatment: Is More Extensive Surgical Resection Beneficial in All Patients?. <i>Annals of Surgical Oncology</i> , 2010, 17, 40-44. | 0.7 | 131 |
| 99 | Survival and the Sentinel Lymph Node in Melanoma. <i>Annals of Surgical Oncology</i> , 2010, 17, 18-20. | 0.7 | 4 |
| 100 | Sentinel node biopsy in melanoma: Technical considerations of the procedure as performed at the John Wayne Cancer Institute. <i>Journal of Surgical Oncology</i> , 2010, 101, 669-676. | 0.8 | 65 |
| 101 | The Impact on Morbidity and Length of Stay of Early Versus Delayed Complete Lymphadenectomy in Melanoma: Results of the Multicenter Selective Lymphadenectomy Trial (I). <i>Annals of Surgical Oncology</i> , 2010, 17, 3324-3329. | 0.7 | 177 |
| 102 | mRNA Expression and BRAF Mutation in Circulating Melanoma Cells Isolated from Peripheral Blood with High Molecular Weight Melanoma-Associated Antigen-Specific Monoclonal Antibody Beads. <i>Clinical Chemistry</i> , 2009, 55, 757-764. | 1.5 | 71 |
| 103 | Improved Survival for Stage IV Melanoma From an Unknown Primary Site. <i>Journal of Clinical Oncology</i> , 2009, 27, 3489-3495. | 0.8 | 95 |
| 104 | Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Vaccination with an Allogeneic Whole-Cell Melanoma Vaccine. <i>Clinical Cancer Research</i> , 2009, 15, 7029-7035. | 3.2 | 82 |
| 105 | Solitary Dermal Melanoma: Beginning or End of the Metastatic Process?. <i>Annals of Surgical Oncology</i> , 2009, 16, 578-584. | 0.7 | 34 |
| 106 | Age-Related Lymphatic Dysfunction in Melanoma Patients. <i>Annals of Surgical Oncology</i> , 2009, 16, 1548-1552. | 0.7 | 92 |
| 107 | Survival impact of sentinel lymphadenectomy. <i>Expert Review of Dermatology</i> , 2009, 4, 5-8. | 0.3 | 0 |
| 108 | Does specialized surgical training increase lymph node yield in colon cancer?. <i>American Surgeon</i> , 2009, 75, 887-91. | 0.4 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Activation of CCR9/CCL25 in Cutaneous Melanoma Mediates Preferential Metastasis to the Small Intestine. <i>Clinical Cancer Research</i> , 2008, 14, 638-645. | 3.2 | 141 |
| 110 | Importance of Sentinel Lymph Node Biopsy in Patients With Thin Melanoma. <i>Archives of Surgery</i> , 2008, 143, 892. | 2.3 | 116 |
| 111 | A Comparison of 3 Tumor Markers (MIA, TA90IC, S100B) in Stage III Melanoma Patients. <i>Cancer Investigation</i> , 2007, 25, 285-293. | 0.6 | 28 |
| 112 | Surgery and Sentinel Lymph Node Biopsy. <i>Seminars in Oncology</i> , 2007, 34, 498-508. | 0.8 | 29 |
| 113 | Can Surgical Therapy Alone Achieve Long-Term Cure of Melanoma Metastatic to Regional Nodes?. <i>Cancer Journal (Sudbury, Mass)</i> , 2006, 12, 207-211. | 1.0 | 20 |
| 114 | The Promise of Metastasectomy in Melanoma. <i>Annals of Surgical Oncology</i> , 2006, 13, 607-609. | 0.7 | 5 |
| 115 | Dendritic cells in melanoma immunotherapy. <i>Current Treatment Options in Oncology</i> , 2005, 6, 175-184. | 1.3 | 3 |
| 116 | Melanoma-inhibiting activity assay predicts survival in patients receiving a therapeutic cancer vaccine after complete resection of american joint committee on cancer stage III melanoma. <i>Annals of Surgical Oncology</i> , 2004, 11, 85-93. | 0.7 | 10 |
| 117 | Radiofrequency Ablation of Hepatic Malignancies: Inexpensive and Minimally Invasive but Should It Replace Resection?. <i>Annals of Surgical Oncology</i> , 2003, 10, 1002-1004. | 0.7 | 12 |
| 118 | Rapid High Efficiency Sensitization of CD8+ T Cells to Tumor Antigens by Dendritic Cells Leads to Enhanced Functional Avidity and Direct Tumor Recognition Through an IL-12-Dependent Mechanism. <i>Journal of Immunology</i> , 2003, 171, 2251-2261. | 0.4 | 126 |
| 119 | Intranodal Administration of Peptide-Pulsed Mature Dendritic Cell Vaccines Results in Superior CD8+ T-Cell Function in Melanoma Patients. <i>Journal of Clinical Oncology</i> , 2003, 21, 3826-3835. | 0.8 | 168 |
| 120 | Melanoma: is immunotherapy of benefit?. <i>Advances in Surgery</i> , 2003, 37, 139-69. | 0.6 | 11 |
| 121 | Revolutionary impact of lymphoscintigraphy and intraoperative sentinel node mapping in the clinical practice of oncology. <i>Seminars in Nuclear Medicine</i> , 2001, 31, 158-164. | 2.5 | 22 |
| 122 | Calcium signaling inhibits interleukin-12 production and activates CD83+ dendritic cells that induce Th2 cell development. <i>Blood</i> , 2001, 98, 2489-2497. | 0.6 | 63 |
| 123 | Calcium ionophore activation of chronic myelogenous leukemia progenitor cells into dendritic cells is mediated by calcineurin phosphatase. <i>Leukemia Research</i> , 2000, 24, 795-804. | 0.4 | 12 |
| 124 | Active Macromolecule Uptake by Lymph Node Antigen-Presenting Cells: A Novel Mechanism in Determining Sentinel Lymph Node Status. <i>Annals of Surgical Oncology</i> , 2000, 7, 98-105. | 0.7 | 48 |
| 125 | Incidence of Sentinel Node Metastasis in Patients With Thin Primary Melanoma (#1 mm) With Vertical Growth Phase. <i>Annals of Surgical Oncology</i> , 2000, 7, 262-267. | 0.7 | 173 |
| 126 | Use of Gastrostomy and Combined Gastrojejunostomy Tubes for Enteral Feeding. <i>World Journal of Surgery</i> , 1999, 23, 603-607. | 0.8 | 22 |